Overview: Written in a handbook format with clinical tips for a variety of medical professionals.Discusses epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of rheumatic ir.With the increasing use of immune checkpoint inhibitors (ICI) across various cancers, the trends for indication at earlier stages, and the use of combination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit
|